Clinical trial · Observational
STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands
NCT04470921CI-TRIAL-00073317STOPOVCAunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to optimize implementation of the opportunistic salpingectomy throughout the Netherlands.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Risk Reduction | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Opportunistic Salpingectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Choice for Opportunistic Salpingectomy
- description
- Women who will undergo a gynaecological surgery in which currently both ovaries and fallopian tubes would be preserved, can opt for an opportunistic salpingectomy.
- interventionNames
- Procedure: Opportunistic Salpingectomy
Primary outcomes (2)
- measure
- Offered Opportunistic Salpingectomy (OS)
- timeFrame
- 2019 - 2023
- description
- Number of eligible women who have actually been offered an opportunistic salpingectomy in the Netherlands.
- measure
- Implementation effect of Opportunistic Salpingectomy (OS)
- timeFrame
- 2019-2023
- description
- The effect of our implementation efforts on the number of eligible women who have actually been offered an opportunistic salpingectomy in the Netherlands.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Age from 30 years * Undergoing gynaecological surgery in which currently both ovaries and fallopian tubes would be preserved * Childbearing completed * Able to understand the written or spoken Dutch language * Consent for enrolment in database * Consent for yearly checks of PALGA database and municipal administration Exclusion Criteria: * Age under 30 years * Undergoing surgery without residual ovarian tissue * Child wish * Unable to understand the written or spoken Dutch language * Previous bilateral salpingectomy * Previous bilateral salpingo-oophorectomy
References
Publications (6)
- BACKGROUNDYoon SH, Kim SN, Shim SH, Kang SB, Lee SJ. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis. Eur J Cancer. 2016 Mar;55:38-46. doi: 10.1016/j.ejca.2015.12.003. Epub 2016 Jan 8. PMID 26773418
- BACKGROUNDKwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, Gilks CB, Huntsman DG. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol. 2015 Feb;125(2):338-345. doi: 10.1097/AOG.0000000000000630. PMID 25568991
- BACKGROUNDvan Lieshout LAM, Steenbeek MP, De Hullu JA, Vos MC, Houterman S, Wilkinson J, Piek JM. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. Cochrane Database Syst Rev. 2019 Aug 28;8(8):CD012858. doi: 10.1002/14651858.CD012858.pub2. PMID 31456223
- BACKGROUNDSteenbeek MP, van Lieshout LAM, Aarts JWM, Piek JMJ, Coppus SFPJ, Massuger LFAG, Hermens RPMG, de Hullu JA. Factors influencing decision-making around opportunistic salpingectomy: a nationwide survey. J Gynecol Oncol. 2019 Jan;30(1):e2. doi: 10.3802/jgo.2019.30.e2. Epub 2018 Apr 30. PMID 30479086
- BACKGROUNDCommittee opinion no. 620: Salpingectomy for ovarian cancer prevention. Obstet Gynecol. 2015 Jan;125(1):279-281. doi: 10.1097/01.AOG.0000459871.88564.09. PMID 25560145
- BACKGROUNDSalvador S, Scott S, Francis JA, Agrawal A, Giede C. No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population. J Obstet Gynaecol Can. 2017 Jun;39(6):480-493. doi: 10.1016/j.jogc.2016.12.005. PMID 28527613